Published in N Engl J Med on November 18, 2013
Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions (CORAL) | NCT00081731
Measuring low-value care in Medicare. JAMA Intern Med (2014) 3.39
Changes in Low-Value Services in Year 1 of the Medicare Pioneer Accountable Care Organization Program. JAMA Intern Med (2015) 3.01
Autologous Mesenchymal Stem Cells Increase Cortical Perfusion in Renovascular Disease. J Am Soc Nephrol (2017) 1.41
Renal Artery Stent Outcomes: Effect of Baseline Blood Pressure, Stenosis Severity, and Translesion Pressure Gradient. J Am Coll Cardiol (2015) 1.40
Lipid, blood pressure and kidney update 2013. Int Urol Nephrol (2014) 1.05
Optimal management of renal artery fibromuscular dysplasia. Ther Clin Risk Manag (2014) 1.03
Mitochondrial protection restores renal function in swine atherosclerotic renovascular disease. Cardiovasc Res (2014) 0.97
Management of atherosclerotic renovascular disease after Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL). Nephrol Dial Transplant (2014) 0.95
Paradigm Shifts in Atherosclerotic Renovascular Disease: Where Are We Now? J Am Soc Nephrol (2015) 0.92
Renal artery stenosis-when to screen, what to stent? Curr Atheroscler Rep (2014) 0.92
Mitochondria: a pathogenic paradigm in hypertensive renal disease. Hypertension (2014) 0.88
Biomarkers of kidney injury and klotho in patients with atherosclerotic renovascular disease. Clin J Am Soc Nephrol (2014) 0.87
Assessment and management of resistant hypertension. CMAJ (2014) 0.86
Renal artery stenosis: epidemiology and treatment. Int J Nephrol Renovasc Dis (2014) 0.85
Predictive role of renal resistive index for clinical outcome after revascularization in hypertensive patients with atherosclerotic renal artery stenosis: a monocentric observational study. Cardiovasc Ultrasound (2014) 0.84
Intrarenal Delivery of Mesenchymal Stem Cells and Endothelial Progenitor Cells Attenuates Hypertensive Cardiomyopathy in Experimental Renovascular Hypertension. Cell Transplant (2014) 0.83
Intra-renal delivery of mesenchymal stem cells attenuates myocardial injury after reversal of hypertension in porcine renovascular disease. Stem Cell Res Ther (2015) 0.83
Renal Therapeutic Angiogenesis Using a Bioengineered Polymer-Stabilized Vascular Endothelial Growth Factor Construct. J Am Soc Nephrol (2015) 0.83
Stenting for renal-artery stenosis. N Engl J Med (2014) 0.83
Management of hypertension in CKD: beyond the guidelines. Adv Chronic Kidney Dis (2015) 0.83
Hypertension-attributed nephropathy: what's in a name? Nat Rev Nephrol (2015) 0.82
Stenting for renal-artery stenosis. N Engl J Med (2014) 0.82
Stenting for renal-artery stenosis. N Engl J Med (2014) 0.82
Attenuation of hypertension and renal damage in renovascular hypertensive rats by iron restriction. Hypertens Res (2016) 0.82
Stenting for renal-artery stenosis. N Engl J Med (2014) 0.81
Gained in translation: protective paradigms for the poststenotic kidney. Hypertension (2015) 0.81
Stenting for renal-artery stenosis. N Engl J Med (2014) 0.81
Metabolomics of renal venous plasma from individuals with unilateral renal artery stenosis and essential hypertension. J Hypertens (2015) 0.81
Endothelin-a receptor antagonism after renal angioplasty enhances renal recovery in renovascular disease. J Am Soc Nephrol (2014) 0.81
Doubly blind: a systematic review of gender in randomised controlled trials. Glob Health Action (2016) 0.80
Blockade of CCR2 reduces macrophage influx and development of chronic renal damage in murine renovascular hypertension. Am J Physiol Renal Physiol (2015) 0.80
Non-contrast-enhanced MRA of renal artery stenosis: validation against DSA in a porcine model. Eur Radiol (2015) 0.80
Update on intervention versus medical therapy for atherosclerotic renal artery stenosis. J Vasc Surg (2015) 0.80
Use of renin-angiotensin inhibitors in people with renal artery stenosis. Clin J Am Soc Nephrol (2014) 0.80
Recognition and Management of Resistant Hypertension. Clin J Am Soc Nephrol (2016) 0.80
Chronic renal ischemia in humans: can cell therapy repair the kidney in occlusive renovascular disease? Physiology (Bethesda) (2015) 0.79
Differences in GFR and Tissue Oxygenation, and Interactions between Stenotic and Contralateral Kidneys in Unilateral Atherosclerotic Renovascular Disease. Clin J Am Soc Nephrol (2016) 0.79
Atherosclerotic renal artery stenosis. Ann Transl Med (2017) 0.78
Relationship of Albuminuria and Renal Artery Stent Outcomes: Results From the CORAL Randomized Clinical Trial (Cardiovascular Outcomes With Renal Artery Lesions). Hypertension (2016) 0.78
Hypertension Treatment for Patients with Advanced Chronic Kidney Disease. Curr Cardiovasc Risk Rep (2014) 0.78
Effects of Stenting for Atherosclerotic Renal Artery Stenosis on eGFR and Predictors of Clinical Events in the CORAL Trial. Clin J Am Soc Nephrol (2016) 0.78
Resistive intrarenal index: myth or reality? Br J Radiol (2014) 0.78
Determination of Single-Kidney Glomerular Filtration Rate in Human Subjects by Using CT. Radiology (2015) 0.77
Management of renal artery stenosis: What does the experimental evidence tell us? World J Cardiol (2014) 0.77
What is the optimal treatment for patients with atherosclerotic renal artery stenosis? Am J Kidney Dis (2014) 0.77
Regional and physician specialty-associated variations in the medical management of atherosclerotic renal-artery stenosis. J Am Soc Hypertens (2015) 0.77
Decrease of glomerular filtration rate may be attributed to the microcirculation damage in renal artery stenosis. Chin Med J (Engl) (2015) 0.77
Is time of renal hypoperfusion an important variable in determining response to renal artery revascularization? JACC Cardiovasc Interv (2014) 0.77
Renal artery stenosis: if and when to intervene. Curr Opin Nephrol Hypertens (2016) 0.76
Atherosclerotic renal artery stenosis: current status. Adv Chronic Kidney Dis (2015) 0.76
Concomitant coronary and renal revascularization improves left ventricular hypertrophy more than coronary stenting alone in patients with ischemic heart and renal disease. J Zhejiang Univ Sci B (2016) 0.76
Changes in inflammatory biomarkers after renal revascularization in atherosclerotic renal artery stenosis. Nephrol Dial Transplant (2016) 0.76
Does Renal Artery Stenting Prevent Clinical Events? Clin J Am Soc Nephrol (2016) 0.76
Stenting for renal-artery stenosis. N Engl J Med (2014) 0.75
Renovascular hypertension 2014: what have we learned from CORAL? J Hum Hypertens (2014) 0.75
Do kidneys need blood? Eur J Vasc Endovasc Surg (2014) 0.75
Long-Term Outcomes and Causes of Death in Patients With Renovascular Disease Undergoing Renal Artery Stenting. Angiology (2015) 0.75
Stent sizing strategies in renal artery stenting: the comparison of conventional invasive renal angiography with renal computed tomographic angiography. Postepy Kardiol Interwencyjnej (2016) 0.75
Surgical, interventional, and device innovations in the management of hypertension. Int J Angiol (2015) 0.75
The perioperative effect of concomitant procedures during open infrarenal abdominal aortic aneurysm repair. J Vasc Surg (2016) 0.75
Hypercholesterolemia Impairs Nonstenotic Kidney Outcomes After Reversal of Experimental Renovascular Hypertension. Am J Hypertens (2016) 0.75
Effects of Restoration of Blood Flow on the Development of Aortic Atherosclerosis in ApoE-/- Mice With Unilateral Renal Artery Stenosis. J Am Heart Assoc (2016) 0.75
Development of renal atrophy in murine 2 kidney 1 clip hypertension is strain independent. Res Vet Sci (2016) 0.75
Analysis of Renal Artery Stenosis in Patients with Heart Failure: A RASHEF Study. Chin Med J (Engl) (2015) 0.75
Accuracy of unenhanced magnetic resonance angiography for the assessment of renal artery stenosis. Eur J Radiol Open (2016) 0.75
Management of vascular risk factors in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). J Am Heart Assoc (2014) 0.75
Transcatheter therapies for resistant hypertension: Clinical review. World J Cardiol (2014) 0.75
Plasma Renin Activity Predicts the Improvement in Resistant Hypertension after Percutaneous Transluminal Renal Artery Angioplasty. Intern Med (2016) 0.75
Endovascular versus medical therapy for atherosclerotic renovascular disease. Curr Atheroscler Rep (2014) 0.75
Treatment of atherosclerotic renovascular disease. N Engl J Med (2013) 0.75
Urinary Mitochondrial DNA Copy Number Identifies Chronic Renal Injury in Hypertensive Patients. Hypertension (2016) 0.75
Renal artery stent in solitary functioning kidneys: 77% of benefit: A systematic review with meta-analysis. Medicine (Baltimore) (2016) 0.75
Preoperative optimization of the vascular surgery patient. Vasc Health Risk Manag (2015) 0.75
Renal Arterial Disease and Hypertension. Med Clin North Am (2017) 0.75
Transcatheter renal interventions: a review of established and emerging procedures. J Clin Imaging Sci (2015) 0.75
How to measure renal artery stenosis - a retrospective comparison of morphological measurement approaches in relation to hemodynamic significance. BMC Med Imaging (2015) 0.75
Kissing stenting of aorto-ostial lesions in juxtaposed renal arteries. BMJ Case Rep (2014) 0.75
The importance of proteinuria and prior cardiovascular disease in all major clinical outcomes of atherosclerotic renovascular disease - a single-center observational study. BMC Nephrol (2016) 0.75
Endovascular Management of Atherosclerotic Renal Artery Stenosis: Post-Cardiovascular Outcomes in Renal Atherosclerotic Lesions Era Winner or False Alarm? Vasc Specialist Int (2017) 0.75
An alternative empirical likelihood method in missing response problems and causal inference. Stat Med (2016) 0.75
Multimarker assessment for the prediction of renal function improvement after percutaneous revascularization for renal artery stenosis. Cardiovasc Diagn Ther (2016) 0.75
Sympathoactivation and rho-kinase-dependent baroreflex function in experimental renovascular hypertension with reduced kidney mass. BMC Physiol (2014) 0.75
Approach to atherosclerotic renovascular disease: 2016. Clin Kidney J (2016) 0.75
Etiology of renal artery stenosis in 2047 patients: a single-center retrospective analysis during a 15-year period in China. J Hum Hypertens (2015) 0.75
Secondary hypertension in adults. Singapore Med J (2016) 0.75
Renal Artery Stenosis in a Young Female without Fibromuscular Dysplasia with Literature Review. Clin Med Insights Cardiol (2016) 0.75
Resistive index as a predictor of renal progression in patients with moderate renal dysfunction regardless of angiotensin converting enzyme inhibitor or angiotensin receptor antagonist medication. Kidney Res Clin Pract (2017) 0.75
Anthropometric and Metabolic Risk Factors for ESRD Are Disease-Specific: Results from a Large Population-Based Cohort Study in Austria. PLoS One (2016) 0.75
Low-Energy Shockwave Therapy Improves Ischemic Kidney Microcirculation. J Am Soc Nephrol (2016) 0.75
Hemodynamic and neural responses to renal denervation of the nerve to the clipped kidney by cryoablation in two-kidney, one-clip hypertensive rats. Am J Physiol Regul Integr Comp Physiol (2015) 0.75
Obesity and renovascular disease. Am J Physiol Renal Physiol (2015) 0.75
Use of renin-angiotensin system blockade in patients with renal artery stenosis. Clin J Am Soc Nephrol (2014) 0.75
Rebuttal from Jens Jordan. J Physiol (2014) 0.75
Choosing Wisely: The Canadian Society of Nephrology's List of 5 Items Physicians and Patients Should Question. Can J Kidney Health Dis (2017) 0.75
A simple score for predicting renal artery stenosis in patients with ischemic heart disease. Int J Clin Exp Med (2015) 0.75
Novel Ti-Ta-Hf-Zr alloys with promising mechanical properties for prospective stent applications. Sci Rep (2016) 0.75
Novel insights into renovascular hypertension and cardio-renal protection by iron restriction. Hypertens Res (2016) 0.75
Renal artery stenosis presenting with nephrotic-range proteinuria: a case report. Kidney Res Clin Pract (2015) 0.75
Mortality and Renal Replacement Therapy after Renal Artery Stent Placement for Atherosclerotic Renovascular Disease. J Vasc Interv Radiol (2016) 0.75
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med (2006) 20.27
STUDIES ON EXPERIMENTAL HYPERTENSION : I. THE PRODUCTION OF PERSISTENT ELEVATION OF SYSTOLIC BLOOD PRESSURE BY MEANS OF RENAL ISCHEMIA. J Exp Med (1934) 14.72
Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med (2009) 10.60
The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med (2000) 4.81
Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med (2009) 4.20
Effect of renal-artery stenting on progression of renovascular renal failure. Lancet (1997) 3.89
Evaluation of the safety and effectiveness of renal artery stenting after unsuccessful balloon angioplasty: the ASPIRE-2 study. J Am Coll Cardiol (2005) 2.87
Prevalence of renovascular disease in the elderly: a population-based study. J Vasc Surg (2002) 2.69
Treatment of ostial renal-artery stenoses with vascular endoprostheses after unsuccessful balloon angioplasty. N Engl J Med (1997) 2.34
Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group. Hypertension (1998) 1.99
Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J (2006) 1.98
Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. Scottish and Newcastle Renal Artery Stenosis Collaborative Group. J Hum Hypertens (1998) 1.96
Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catheterization. J Am Soc Nephrol (1992) 1.92
Significant reduction in systolic blood pressure following renal artery stenting in patients with uncontrolled hypertension: results from the HERCULES trial. Catheter Cardiovasc Interv (2012) 1.79
Renal artery stenosis and hypertension. Lancet (1994) 1.67
Increase in utilization of percutaneous renal artery interventions by medicare beneficiaries, 1996-2000. AJR Am J Roentgenol (2004) 1.65
Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis. Hypertension (2010) 1.47
Effect of renal artery stenting on renal function and size in patients with atherosclerotic renovascular disease. Circulation (2000) 1.42
Prevalence of atherosclerotic renal artery stenosis in patients with atherosclerosis elsewhere. Am J Med (1990) 1.39
Renal artery angioplasty and stent placement: predictors of a favorable outcome. Am Heart J (2000) 1.29
Renal artery stenting with noninvasive duplex ultrasound follow-up: 3-year results from the RENAISSANCE renal stent trial. Catheter Cardiovasc Interv (2008) 1.13
Renovascular hypertension. Curr Opin Nephrol Hypertens (1997) 1.06
Revascularization in renal artery stenosis. Cardiol Rev (2012) 1.05
Determinants of renal function in patients with renal artery stenosis. Vasc Med (2011) 1.03
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29
Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care (2003) 29.49
General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation (2008) 26.42
Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med (2010) 17.57
Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med (2010) 14.49
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation (2007) 12.79
Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med (2004) 12.58
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA (2002) 12.29
Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med (2004) 11.46
Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med (2002) 11.20
Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol (2007) 9.90
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med (2008) 9.68
Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med (2015) 9.58
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 8.90
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 8.80
Incidence of diabetes in youth in the United States. JAMA (2007) 8.70
Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med (2007) 8.59
Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation (2005) 8.54
Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation (2002) 8.49
Application of new cholesterol guidelines to a population-based sample. N Engl J Med (2014) 8.22
The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol (2003) 7.79
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol (2003) 7.47
Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet (2009) 7.27
The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics (2006) 7.19
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension (2008) 6.96
Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA (2007) 6.95
Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med (2002) 6.92
Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA (2002) 6.84
Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation (2003) 6.83
Obesity and the risk of new-onset atrial fibrillation. JAMA (2004) 6.73
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet (2012) 6.69
Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med (2004) 6.42
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36
Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation (2007) 6.34
Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med (2007) 6.29
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation (2006) 5.97
Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation (2008) 5.95
Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med (2011) 5.94
Percutaneous repair or surgery for mitral regurgitation. N Engl J Med (2011) 5.78
Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med (2007) 5.77
A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study. BMC Med Genet (2007) 5.64
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension (2003) 5.47
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37
Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA (2004) 5.34
Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab (2006) 5.33
Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA (2013) 5.31
Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation (2008) 5.26
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res (2009) 5.20
Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation (2011) 5.16
Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation (2007) 5.10
The Framingham Heart Study 100K SNP genome-wide association study resource: overview of 17 phenotype working group reports. BMC Med Genet (2007) 5.02
Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol (2007) 4.99
A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol (2005) 4.95
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA (2006) 4.90
Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA (2004) 4.85
Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA (2013) 4.81
A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA (2003) 4.77
Trends in cardiovascular complications of diabetes. JAMA (2004) 4.74
Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med (2008) 4.72
A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes: results from the National Health and Examination Survey 1999-2002. Diabetes Care (2006) 4.66
Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA (2004) 4.63
Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Arch Intern Med (2008) 4.63
Predicting the 30-year risk of cardiovascular disease: the framingham heart study. Circulation (2009) 4.62
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med (2015) 4.62
A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study. Ann Intern Med (2008) 4.61
Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study. Stroke (2004) 4.56
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med (2011) 4.34
Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med (2015) 4.27
Estimating treatment effects using observational data. JAMA (2007) 4.12